Computer Software Assurance (CSA) per FDA 2022

Our services for Computer Software Assurance (CSA)

System classification: GAMP category and CSA risk assessment (Category A / B)
Creation of the complete CSV document package (VP, URS, FS, DS, test protocols IQ/OQ/PQ, VR)
CSA implementation per FDA Guidance 2022: process setup, templates, training
Vendor assessment and supplier audits for GxP software providers
Gap analysis of existing validation documentation
Re-validation after system changes or version upgrades
Data migration validation (data migration in regulated systems)
Audit preparation and inspection support (FDA, EMA, authorities)
Training of your QA and IT teams on CSV and CSA

Clarify scope?

Book an intro call

CSA-Wegweiser

Welche Ausgangslage beschreibt Ihr System?

Wählen Sie die Ausgangslage. Sie erhalten einen fokussierten Startpunkt mit passenden Vertiefungen und einem direkten Kontaktweg.

Einführung mit CSA-Ansatz

Wir bewerten GxP-Kritikalität, nutzen Herstellernachweise und fokussieren Tests auf geschäftskritische Funktionen.

CSA besprechen CSV-Grundlagen ansehen

CSA is not a new legal frame but a method inside the existing one. What remains binding is FDA 21 CFR Part 11 (electronic records and signatures), EU GMP Annex 11 (computerised systems) and the GAMP 5 framework from ISPE.

Our approach in GxP projects: from planning through release – each step delivers evidence you can present in QA review and audit. View GxP consulting in five steps

Starting Point: The Regulatory Frame

What the evidence has to cover is described under Computer System Validation (CSV). This page answers the follow-on question: how deeply you test, and what sets that depth.

Scope examples: LIMS, ERP (SAP), EDMS, MES/SCADA, eTMF, CTMS, laboratory instruments with software, data historian systems, data migration projects, cloud applications in the GxP environment.

Traditional CSV Process

The classical CSV approach follows the V-model and is primarily documentation-oriented: a complete document package is created for each system, and each test level is formally recorded and approved.

Validation Plan

Scope, roles, timeline, acceptance criteria: the foundation of every CSV project.

URS / FS / DS

Complete specification hierarchy: User Requirements, Functional Spec, Design Spec.

IQ / OQ / PQ

Three-stage qualification: Installation, Operational, Performance, with protocols and deviation management.

Validation Report

Summary of all test results, open items and formal system release.

Computer Software Assurance (CSA) FDA 2022

In September 2022, the FDA published the final Guidance "Computer Software Assurance for Production and Quality System Software": a paradigm shift from the previous GAMP-5-centred CSV practice. CSA is not intended as a replacement for CSV, but as a modern framework for a risk-based, efficiency-oriented implementation.

The key difference: while traditional CSV is heavily documentation-oriented, CSA puts testing over documenting at the forefront. The FDA states it directly: less documentation effort, more focus on actual testing activities that address risks.

Category A vs. Category B

CSA distinguishes two software categories based on their impact on product quality and patient safety:

Category A

Lower GxP Criticality

Software that supports GxP processes but has no direct impact on product quality or patient safety. Simplified assurance activities are sufficient.

Examples: Office tools for regulated documents, time-tracking systems, HR tools in GxP companies

Category B

High GxP Criticality

Software with direct impact on product quality, patient safety or regulated data integrity. Comprehensive assurance required, but more efficient than classical CSV.

Examples: LIMS, MES, QMS, SCADA, eTMF, clinical databases (EDC), batch record systems

CSV vs. CSA: Direct Comparison

Attribute	Traditional CSV	CSA (FDA 2022)
Focus	Documentation evidence	Testing activities and risk mitigation
Documentation volume	High: complete SDLC document set	Risk-based reduction: "critical thinking" determines scope
Testing depth	Formally recorded at all levels	Proportional to risk, more testing, less paper documentation
Validation plan	Mandatory, detailed	Simplified for Cat. A, full for Cat. B
Vendor documentation	Extensively required	Manufacturer evidence can reduce validation effort
Time investment	High	Significantly lower for Category A systems
Regulatory basis	GAMP 5, 21 CFR Part 11, Annex 11	FDA Guidance Sept. 2022, compatible with GAMP 5 (2nd Ed.)
Applicability	All GxP-regulated systems	Primarily FDA scope; EMA compatibility evolving

Benefits of CSA for Your Organisation

Faster System Deployment

Risk-based validation significantly reduces documentation effort for Category A systems. Systems can be brought into validated operation more quickly, without regulatory compromise.

More Test Quality, Less Paperwork

CSA shifts the effort from document creation to actual testing. This increases real system quality while simultaneously reducing bureaucratic overhead.

Flexibility for Modern IT Architectures

Cloud systems, SaaS applications and agilely developed software are better handled under CSA than under the classical V-model documentation approach.

Better Change Control

Risk-based impact assessment under CSA enables faster evaluation and more efficient re-validation cycles for system updates.

Compatibility with GAMP 5 (2nd Edition 2022)

GAMP 5 (2nd Edition) and CSA were finalised simultaneously and are aligned with each other. Organisations can apply CSA principles within a GAMP 5-compliant framework.

Special Case: Cloud and SaaS in the GxP Environment

Cloud-based systems and SaaS applications pose particular challenges for CSV and CSA: who bears validation responsibility? How is the provider qualified? What happens with uncontrolled updates?

cube one has extensive experience validating cloud GxP systems, from contract design (Shared Responsibility Model) and vendor assessment through to documentation of user controls and ongoing monitoring of system updates.

FAQ: Computer Software Assurance (CSA)

Does CSA apply in the EU / under EU GMP Annex 11?

CSA is formally an FDA guidance and applies primarily in the US-regulated domain. EU GMP Annex 11 does not prescribe a specific validation approach but is clearly principles-based and allows risk-based approaches. In practice, many EU companies apply CSA principles within the Annex 11 framework, especially for international registrations with FDA requirements. Individual regulatory assessment is recommended.

Do already validated systems need to be converted to CSA?

No. CSA is not a mandatory transition. Existing validated systems remain valid. CSA is suitable for new systems, re-validation as part of major updates or process revisions. The decision CSV vs. CSA should be made in a risk-based and strategic manner.

How does CSA relate to GAMP 5 Category 4 and 5?

CSA does not replace GAMP 5, both frameworks are compatible. GAMP 5 categorises the software by type and development effort; CSA assesses risk by GxP impact. Category 4 software (configurable COTS) would typically be classified as CSA Category B and benefits from reduced documentation requirements. Category 5 software (bespoke) still requires a comprehensive validation approach: whether per classical CSV or CSA principles.

What does a CSV or CSA implementation cost?

The effort depends on system complexity, GAMP category, company size and regulatory environment. For systems with low GxP criticality, CSA can substantially reduce documentation and review effort compared with a traditional CSV approach. cube one assesses the potential per system and produces a binding project plan with an effort estimate following an initial scoping workshop.

How is a vendor qualified for a GxP application?

Vendor assessment typically includes: questionnaire on software development processes (SDLC, testing, change control), audit of the development environment (optionally remote), review of available quality documents (IQ packages, test reports, certificates). Under CSA, strong manufacturer evidence (good development process, comprehensive own testing) can significantly reduce internal validation effort.